Treatment options for cachexia had been limited before anamorelin, an orally active, highly selective ghrelin receptor agonist [24], was approved in Japan for patients with cachexia associated with non-small cell lung cancer, gastric cancer, colorectal cancer, and pancreatic cancer. This evidence concerns the gene GHSR and non-small cell lung carcinoma.